MultiPlan Corporation reported Q3 2024 revenues of $230.5 million, a net loss of $391.5 million (including a $361.6 million impairment), and Adjusted EBITDA of $141.6 million. The company identified approximately $6.4 billion in potential medical cost savings during the quarter.
Revenues for Q3 2024 were $230.5 million, a 5.1% decrease compared to Q3 2023.
Net loss for Q3 2024 was $391.5 million, primarily due to a $361.6 million impairment charge.
Adjusted EBITDA for Q3 2024 was $141.6 million, compared to $152.3 million for Q3 2023.
The company processed approximately $44.7 billion in claim charges during Q3 2024, identifying potential medical cost savings of approximately $6.4 billion.
The Company is updating certain metrics for its full-year 2024 guidance. Revenues are expected to be between $930 million and $940 million. Adjusted EBITDA is expected to be between $580 million and $590 million.
Analyze how earnings announcements historically affect stock price performance